IMAS Optimization and Applicability in an Acute Stroke Setting.

Sponsor
Case Western Reserve University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05469438
Collaborator
Highland Instruments, Inc. (Industry)
30
2
11
15
1.4

Study Details

Study Description

Brief Summary

The investigator will investigate our Integrated sensor-based Motion Analysis Suite (IMAS) to objectively and quantitatively measure acute stroke patient motor status.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The investigator will evaluate the feasibility of our IMAS to assess 30 stroke subjects in 5 sessions (the first 4 proximal to stroke onset and the last session ~6-8 weeks post stroke). The investigator will test IMAS in 30 acute stroke subjects; and extract quantitative movement kinematic/kinetic metrics descriptive of subjects' motor behavior (e.g., arm movement speed, smoothness). Subjects will undergo a series of upper limb focused assessments including Fugl Meyer, Barthel Index, and Orpington Prognostic Scale assessments. The investigator will also collect demographics, and stroke clinical information such as imaging data.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    IMAS Optimization and Applicability in an Acute Stroke Setting.
    Actual Study Start Date :
    Oct 29, 2021
    Anticipated Primary Completion Date :
    Aug 31, 2022
    Anticipated Study Completion Date :
    Sep 30, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Biomechanical Assessments of movements from the Fuegl-Meyer Scale. Prediction of motor recovery post-stroke. [6 - 8 weeks post acute stroke onset]

      Biomechanical Evaluations of movements from the Fuegl-Meyer Scale post-stroke. The sensor suite will assess patient movement from the Fuegl-Meyer Scale through kinetics (e.g., time to perform the movement, position, distance, velocity), and kinematics (e.g., angular velocity).

    Secondary Outcome Measures

    1. Barthel Index [6 - 8 weeks post acute stroke onset.]

      The Barthel Index questionnaire measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Providing informed consent to participate in the study.

    2. Age 18 to 85 years old.

    3. Clinical presentation and neuroimaging (CTA-CTP/ MRI-MRA) consistent with the diagnosis of Acute Ischemic or Hemorrhagic Stroke.

    4. Preserved mental status (Glasgow coma score >12: E(4), V(5), M (4-6)).

    5. Presence of upper limb weakness per the NIHSS (1-2 points in the arm) and ability to perform testing (i.e. NIHSS motor score 1-2 at elbow, wrist, and finger flexion extension). (Note that individuals with a prior ischemic or hemorrhagic stroke with available information pertaining superior extremity baseline strength after their previous stroke would qualify).

    6. Baseline Modified Rankin score <4.

    Exclusion Criteria:
    1. History of alcohol or drug abuse within the past 6 months as self-reported;

    2. History of schizophrenia, schizoaffective disorder, other psychosis, bipolar illness, alcohol/drug abuse within the past year;

    3. Need for rapid clinical response due to conditions such as initiation, psychosis, or suicidality;

    4. Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure, pulmonary issues, or chronic obstructive pulmonary disease);

    5. History of dementia per relative/ medical records.

    6. Presence of receptive aphasia at baseline or after the current acute stroke.

    7. Amputated limbs.

    8. Absence of weakness as per the NIHSS (0 points = no drift for motor arm and leg items) or severe motor impairment NIHSS 4 points for motor arm).

    9. Stroke mimics (e.g., infections, medication effects from sedatives, electrolyte imbalances, etc.).

    10. Stroke worsening between assessments.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ciro Ramos Estebanez, MD., Ph.D., MBA, FNCS. Chicago Illinois United States 60612
    2 Maulik Purohit, M.D., MPH Cleveland Ohio United States 44106

    Sponsors and Collaborators

    • Case Western Reserve University
    • Highland Instruments, Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ciro Ramos Estebanez, Clinical Professor, Case Western Reserve University
    ClinicalTrials.gov Identifier:
    NCT05469438
    Other Study ID Numbers:
    • STUDY20190922
    First Posted:
    Jul 21, 2022
    Last Update Posted:
    Jul 21, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ciro Ramos Estebanez, Clinical Professor, Case Western Reserve University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2022